Reports indicate that uniQure's stock has experienced significant movement, with some outlets stating it has skyrocketed, while others note a slide, following an update on the company's Huntington's disease study. The outcome of a recent FDA meeting appears to be a factor in the stock's movement, although the impact of the meeting is unclear, with some sources suggesting a positive development and others indicating a halt to the company's plans. The conflicting reports suggest uncertainty surrounding the study's progress and the company's future prospects.